Can-Fite BioPharma (CANF) Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of AASLD

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that following a late-breaking oral presentation of its Phase II Namodenoson study in the treatment of NAFLD/NASH delivered at the American Association for the Study of Liver Diseases (AASLD) conference, the presentation was selected as ‘Best of The Liver Meeting’ in the NAFLD/NASH category and will be published in the summary slide deck. Inclusion in the Best of the Liver Meeting is a singular honor and indicates the high level with which the AASLD review committee regards the research. These topic-specific slide decks are excellent ways to further showcase important research and will be distributed publicly by AASLD following The Liver Meeting Digital Experience conference.

The study’s Principal Investigator Dr. Rifaat Safadi made the oral presentation titled “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study Of The Efficacy And Safety Of Namodenoson (CF102), An A3 Adenosine Receptor (A3AR) Agonist, In Treating Non-Alcoholic Fatty Liver Disease (NAFLD) And Non-Alcoholic Steatohepatitis (NASH)” on Sunday, November 15, 2020.

“We were very pleased and honored that our Namodenoson NAFLD/NASH study results received this recognition by the AASLD’s review committee, which is comprised of thought leaders in liver disease. Our NASH program has generated strong interest in science and business circles alike, as Namodenoson has shown the potential to be a safe and effective treatment in a disease for which there is currently no approved treatment. We believe inclusion in AASLD’s Best of the Liver Meeting will further highlight our results in the medical community,” said Can-Fite CEO Dr. Pnina Fishman.

You May Also Be Interested In

• Spectral AI, Inc. (MDAI) Appoints Erich Spangenberg as CEO of Spectral IP, Explores Potential Spin-Off
• Kiromic BioPharma (KRBP) Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Trial First Three Patients
• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab